Cargando…
Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves’ Ophthalmopathy to Parenteral Corticosteroids
BACKGROUND: High dose intravenous glucocorticoid (ivGC) therapy is the first line treatment in moderate to severe Graves’ ophthalmopathy (GO) and is associated with a clinical response rate ranging from 50% to 80%. Recently, a positive correlation between total cholesterol and low-density lipoprotei...
Autores principales: | Naselli, Adriano, Moretti, Diletta, Regalbuto, Concetto, Arpi, Maria Luisa, Lo Giudice, Fabrizio, Frasca, Francesco, Belfiore, Antonino, Le Moli, Rosario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784376/ https://www.ncbi.nlm.nih.gov/pubmed/33414766 http://dx.doi.org/10.3389/fendo.2020.609895 |
Ejemplares similares
-
Early Massive Fibrosis of a Single Extraocular Muscle Causing Severe Unilateral Euthyroid Graves’ Ophthalmopathy in a Patient with Hypercholesterolemia Who Smokes
por: Frazzetto, Giuseppe, et al.
Publicado: (2023) -
Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020) -
Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis
por: Tu, Xiaofang, et al.
Publicado: (2018) -
Inflammasome activation as a link between obesity and thyroid disorders: Implications for an integrated clinical management
por: Le Moli, Rosario, et al.
Publicado: (2022) -
Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy?
por: Penta, Laura, et al.
Publicado: (2019)